二酰基甘油激酶在糖尿病肾病改善中的作用。
The Role of Diacylglycerol Kinase in the Amelioration of Diabetic Nephropathy.
机构信息
Department of Applied Chemistry in Bioscience, Graduate School of Agricultural Science, Faculty of Agriculture, Kobe University, Kobe 657-8501, Japan.
出版信息
Molecules. 2022 Oct 11;27(20):6784. doi: 10.3390/molecules27206784.
The drastic increase in the number of patients with diabetes and its complications is a global issue. Diabetic nephropathy, the leading cause of chronic kidney disease, significantly affects patients' quality of life and medical expenses. Furthermore, there are limited drugs for treating diabetic nephropathy patients. Impaired lipid signaling, especially abnormal protein kinase C (PKC) activation by de novo-synthesized diacylglycerol (DG) under high blood glucose, is one of the causes of diabetic nephropathy. DG kinase (DGK) is an enzyme that phosphorylates DG and generates phosphatidic acid, i.e., DGK can inhibit PKC activation under diabetic conditions. Indeed, it has been proven that DGK activation ameliorates diabetic nephropathy. In this review, we summarize the involvement of PKC and DGK in diabetic nephropathy as therapeutic targets, and its mechanisms, by referring to our recent study.
糖尿病患者及其并发症数量的急剧增加是一个全球性问题。糖尿病肾病是导致慢性肾脏病的主要原因，严重影响患者的生活质量和医疗费用。此外，用于治疗糖尿病肾病患者的药物有限。脂质信号受损，特别是在高血糖下由新合成的二酰基甘油（DG）引起的异常蛋白激酶 C（PKC）激活，是糖尿病肾病的原因之一。二酰基甘油激酶（DGK）是一种将 DG 磷酸化生成磷酸脂的酶，即 DGK 可以在糖尿病条件下抑制 PKC 的激活。事实上，已经证明 DGK 的激活可以改善糖尿病肾病。在这篇综述中，我们通过参考我们最近的研究，总结了 PKC 和 DGK 作为治疗靶点在糖尿病肾病中的作用及其机制。
Zotero 插件